… ProQR Announces Japanese Axiomer™ Patent Upheld Following … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … 2023 with the Japanese Patent Office by a strawman against ProQR’s granted patent JP 7244922 , which is related to the …
… ProQR Announces Positive Top-Line Results from a Phase 1b … improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a … said Noreen R. Henig, M.D, Chief Medical Officer at ProQR. “I want to thank the entire CF community including …
… ProQR to Present its Axiomer® RNA Editing Technology at the … & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation Presentation title: Development of RNA …
… ProQR Announces Top-Line Results from Phase 2/3 Illuminate … Daniel A. de Boer, Founder and CEO of ProQR Therapeutics. “ProQR was founded with the goal of developing RNA therapies … many are feeling in the community,” said Benjamin R. Yerxa, Chief Executive Officer at the Foundation Fighting …
… ProQR Announces Presentations at ECFS on Eluforsen for … LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … CFF Research Conference. Presentation at ECFS Conference ProQR will deliver a short talk (ePoster) and a poster …